4-ethyloctan-4-ol | 38395-42-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-ethyloctan-4-ol
• 英文别名: Aethyl-propyl-butyl-carbinol；Ethyl-propyl-butyl-carbinol；4-Ethyl-octanol-(4)；4-Aethyloktanol-4；1-ethyl-1-n-propyl-n-pentanol；ethyl-1-n-propyl-n-pentanol；4-Aethyl-octan-4-ol
• CAS: 38395-42-5
• 化学式: C₁₀H₂₂O
• 分子量: 158.284
• InChiKey: OYBUBRUQIKTRET-UHFFFAOYSA-N

物化性质

• 沸点：
  88.8-89.4 °C(Press: 15 Torr)
• 密度：
  0.8369 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2905199090

反应信息

• 作为反应物：
  描述：

  4-ethyloctan-4-ol 生成 4-乙基辛烷
  参考文献：
  名称：

  Shakhovskoi,B.G. et al., Journal of general chemistry of the USSR, 1965, vol. 35, p. 1036 - 1040

  摘要：

  DOI：
• 作为产物：
  描述：

  丙基溴化镁 、 3-庚酮 以 乙醚 为溶剂， 以80%的产率得到4-ethyloctan-4-ol
  参考文献：
  名称：

  以伯叔烷基胺为基石的方法

  摘要：

  初级叔烷基胺包括金刚烷胺的类似物，通常连接到药效基团的片段，以提高生物活性。伯叔烷基胺的制备被认为是一个难题。四个合成步骤，其中一些已经用于与胺的合成已有报道初级（RCH 2 NH 2）或仲（RR'CHNH 2）烷基和/或芳基，伯合成进行了测试叔烷基胺（RR'R''CNH 2）包括金刚烷加合物在内的脂族系列。这些程序包括在形成和还原的叔烷基叠氮化物，在标准和改良条件Ritter反应，在加入有机金属试剂以ñ -叔丁基亚磺酰基酮亚胺和一锅在路易斯酸的存在下，Τi（IPRO）腈和有机金属试剂之间的反应4或CeCl 3.对于伯叔烷基胺，尚未开发这些合成途径。当前缺乏对伯叔烷基胺的合成路线的研究。研究了每种方法的反应条件和底物限制，第一种方法是最通用的方法，也适用于带有大分子加合物的化合物。

  DOI：

  10.1016/j.tet.2019.06.016

文献信息

• Secondary amines
  申请人：Labaz

  公开号：US04201725A1

  公开（公告）日：1980-05-06

  Methylamine derivatives of the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein R.sub.1 and R.sub.3 each represent a hydrogen atom or a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 1 to 6 carbon atoms, R.sub.2 represents a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 2 to 7 carbon atoms with the proviso that when R.sub.2 represents an alkenyl radical of the formula CH.dbd.CH--R.sub.6 or an alkynyl radical of the formula C.tbd.C--R.sub.6, in which R.sub.6 represents a hydrogen atom or a straight- or branched-chain alkyl radical of 1 to 5 carbon atoms, R.sub.1 and R.sub.3 each represent an atom of hydrogen or an alkyl radical, R.sub.4 and R.sub.5, which are the same or different, each respresent a hydrogen atom, a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 1 to 5 carbon atoms or an .omega.-hydroxyalkyl radical containing from 2 to 5 carbon atoms or R.sub.4 and R.sub.5, when they are taken together represent an alkylene radical containing from 2 to 6 carbon atoms, an alkylidene radical containing from 1 to 5 carbon atoms or the radical --CH.sub.2 --CH.sub.2 --O--CH.sub.2 --CH.sub.2 --, R.sub.1, R.sub.2 and R.sub.3 being such that the trisubstituted methylamine radical possesses no more than 13 carbon atoms. They are useful for treating Parkinson's disease and for correcting extra-pyramidal disturbances provoked by neuroleptics.

  甲基胺衍生物的公式为：##STR1##以及药学上可接受的酸加成盐，其中R.sub.1和R.sub.3各自代表一个氢原子或一个含有1至6个碳原子的直链或支链烷基、烯基或炔基自由基，R.sub.2代表一个含有2至7个碳原子的直链或支链烷基、烯基或炔基自由基，条件是当R.sub.2代表一个公式为CH.dbd.CH--R.sub.6的烯基自由基或一个公式为C.tbd.C--R.sub.6的炔基自由基时，其中R.sub.6代表一个氢原子或一个含有1至5个碳原子的直链或支链烷基自由基，R.sub.1和R.sub.3各自代表一个氢原子或一个烷基自由基，R.sub.4和R.sub.5相同或不同，各自代表一个氢原子，一个含有1至5个碳原子的直链或支链烷基、烯基或炔基自由基，或一个含有2至5个碳原子的ω-羟基烷基自由基，或者R.sub.4和R.sub.5共同代表一个含有2至6个碳原子的亚烷基自由基，一个含有1至5个碳原子的亚烷基自由基或自由基--CH.sub.2 --CH.sub.2 --O--CH.sub.2 --CH.sub.2 --，R.sub.1、R.sub.2和R.sub.3使得三取代甲基胺自由基最多含有13个碳原子。它们可用于治疗帕金森病，并用于纠正由神经阻滞剂引起的锥体外系扰动。
• Active derivatives of methylamine in therapeutic compositions and
  申请人：Labaz

  公开号：US04057644A1

  公开（公告）日：1977-11-08

  Methylamine derivatives of the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein R.sub.1 and R.sub.3 each represent a hydrogen atom or a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 1 to 6 carbon atoms, R.sub.2 represents a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 2 to 7 carbon atoms with the proviso that when R.sub.2 represents an alkenyl radical of the formula CH.dbd.CH--R.sub.6 or an alkynyl radical of the formula C.tbd.C--R.sub.6, in which R.sub.6 represents a hydrogen atom or a straight- or branched-chain alkyl radical of 1 to 5 carbon atoms, R.sub.1 and R.sub.3 each represent an atom of hydrogen or an alkyl radical, R.sub.4 and R.sub.5, which are the same or different, each represent a hydrogen atom, a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 1 to 5 carbon atoms or an .omega.-hydroxyalkyl radical containing from 2 to 5 carbon atoms or R.sub.4 and R.sub.5, when they are taken together represent an alkylene radical containing from 2 to 6 carbon atoms, an alkylidene radical containing from 1 to 5 carbon atoms or the radical --CH.sub.2 --CH.sub.2 --O--CH.sub.2 --CH.sub.2 --, R.sub.1, R.sub.2 and R.sub.3 being such that the trisubstituted methylamine radical possesses no more than 13 carbon atoms. They are useful for treating Parkinson's disease and for correcting extra-pyramidal disturbances provoked by neuroleptics.

  Methylamine derivatives of the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein R.sub.1 and R.sub.3 each represent a hydrogen atom or a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 1 to 6 carbon atoms, R.sub.2 represents a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 2 to 7 carbon atoms with the proviso that when R.sub.2 represents an alkenyl radical of the formula CH.dbd.CH--R.sub.6 or an alkynyl radical of the formula C.tbd.C--R.sub.6, in which R.sub.6 represents a hydrogen atom or a straight- or branched-chain alkyl radical of 1 to 5 carbon atoms, R.sub.1 and R.sub.3 each represent an atom of hydrogen or an alkyl radical, R.sub.4 and R.sub.5, which are the same or different, each represent a hydrogen atom, a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 1 to 5 carbon atoms or an .omega.-hydroxyalkyl radical containing from 2 to 5 carbon atoms or R.sub.4 and R.sub.5, when they are taken together represent an alkylene radical containing from 2 to 6 carbon atoms, an alkylidene radical containing from 1 to 5 carbon atoms or the radical --CH.sub.2 --CH.sub.2 --O--CH.sub.2 --CH.sub.2 --, R.sub.1, R.sub.2 and R.sub.3 being such that the trisubstituted methylamine radical possesses no more than 13 carbon atoms. They are useful for treating Parkinson's disease and for correcting extra-pyramidal disturbances provoked by neuroleptics.
• [EN] PROCESS<br/>[FR] PROCÉDÉ
  申请人：PHOSPHAGENICS LTD

  公开号：WO2018112512A1

  公开（公告）日：2018-06-28

  An efficient and commercial phosphorylation process of a complex alcohol, such as secondary and tertiary alcohols, with P4O10 at high temperatures, and a product obtained by the process.

  一种高效商业化的磷酸酯化过程，用于复杂醇类（如二级和三级醇），在高温下使用P4O10，以及该过程得到的产品。
• Active derivatives of methylamine, therapeutic compositions containing
  申请人：Labaz

  公开号：US04026925A1

  公开（公告）日：1977-05-31

  Methylamine derivatives of the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein R.sub.1 and R.sub.3 each represent a hydrogen atom or a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 1 to 6 carbon atoms, R.sub.2 represents a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 2 to 7 carbon atoms with the proviso that when R.sub.2 represents an alkenyl radical of the formula CH=CH--R.sub.4 or an alkynyl radical of the formula C.tbd.C--R.sub.4, in which R.sub.4 represents a hydrogen atom or a straight- or branched-chain alkyl radical of 1 to 5 carbon atoms, R.sub.1 and R.sub.3 each represent an atom of hydrogen or an alkyl radical, R.sub.1, R.sub.2 and R.sub.3 being such that no compound of formula I possesses more than 13 carbon atoms. They are useful for treating Parkinson's disease and for correcting extra-pyramidal disturbances provoked by neuroleptics.

  甲基胺衍生物的化学式为：##STR1##及其药用可接受的酸盐，其中R.sub.1和R.sub.3分别表示氢原子或含有1至6个碳原子的直链或支链烷基、烯基或炔基基团，R.sub.2表示含有2至7个碳原子的直链或支链烷基、烯基或炔基基团，但当R.sub.2表示化学式CH=CH--R.sub.4的烯基基团或化学式C.tbd.C--R.sub.4的炔基基团时，其中R.sub.4表示氢原子或含有1至5个碳原子的直链或支链烷基基团，R.sub.1和R.sub.3各自表示氢原子或烷基基团，R.sub.1、R.sub.2和R.sub.3使得化合物I的碳原子数不超过13个。它们可用于治疗帕金森病和纠正由神经阻滞剂引起的额外锥体外运动障碍。
• A Study of the Activity of Adamantyl Amines against Mutant Influenza A M2 Channels Identified a Polycyclic Cage Amine Triple Blocker, Explored by Molecular Dynamics Simulations and Solid‐State NMR**
  作者：Μarianna Stampolaki、Anja Hoffmann、Kumar Tekwani、Kyriakos Georgiou、Christina Tzitzoglaki、Chunlong Ma、Stefan Becker、Patrick Schmerer、Kristin Döring、Ioannis Stylianakis、Andreea L. Turcu、Jun Wang、Santiago Vázquez、Loren B. Andreas、Michaela Schmidtke、Antonios Kolocouris

  DOI：10.1002/cmdc.202300182

  日期：2023.8.15

  We compared the anti‐influenza potencies of 57 adamantyl amines and analogs against influenza A virus with serine‐31 M2 proton channel, usually termed as WT M2 channel, which is amantadine sensitive. We also tested a subset of these compounds against viruses with the amantadine‐resistant L26F, V27A, A30T, G34E M2 mutant channels. Four compounds inhibited WT M2 virus in vitro with mid‐nanomolar potency, with 27 compounds showing sub‐micromolar to low micromolar potency. Several compounds inhibited L26F M2 virus in vitro with sub‐micromolar to low micromolar potency, but only three compounds blocked L26F M2‐mediated proton current as determined by electrophysiology (EP). One compound was found to be a triple blocker of WT, L26F, V27A M2 channels by EP assays, but did not inhibit V27A M2 virus in vitro, and one compound inhibited WT, L26F, V27A M2 in vitro without blocking V27A M2 channel. One compound blocked only L26F M2 channel by EP, but did not inhibit virus replication. The triple blocker compound is as long as rimantadine, but could bind and block V27A M2 channel due to its larger girth as revealed by molecular dynamics simulations, while MAS NMR informed on the interaction of the compound with M2(18–60) WT or L26F or V27A.

  摘要 我们比较了57种金刚烷胺及其类似物对具有丝氨酸-31 M2质子通道（通常称为WT M2通道，对金刚烷胺敏感）的甲型流感病毒的抗流感病毒效力。我们还测试了其中一部分化合物对金刚烷胺耐药的 L26F、V27A、A30T、G34E M2 突变通道病毒的抑制作用。四种化合物在体外抑制 WT M2 病毒的效力为中等纳摩尔，27 种化合物的效力为亚微摩尔至低微摩尔。有几种化合物在体外以亚微摩尔至低微摩尔的效力抑制 L26F M2 病毒，但根据电生理学（EP）测定，只有三种化合物阻断了 L26F M2 介导的质子电流。通过 EP 试验发现，一种化合物是 WT、L26F 和 V27A M2 通道的三重阻断剂，但在体外不抑制 V27A M2 病毒；一种化合物在体外抑制 WT、L26F 和 V27A M2，但不阻断 V27A M2 通道。一种化合物通过 EP 只阻断了 L26F M2 通道，但没有抑制病毒复制。分子动力学模拟显示，这种三重阻断剂化合物的长度与利曼他定相当，但由于其周长更大，可以结合并阻断 V27A M2 通道，而 MAS NMR 则显示了该化合物与 M2(18-60) WT 或 L26F 或 V27A 的相互作用。